Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis

Background: In the phase III RECOURSE trial, the orally administered combination trifluridine/tipiracil (FTD/TPI) demonstrated a survival benefit and an acceptable safety profile, earning approval as a third-line therapy in metastatic colorectal cancer (mCRC). This study aimed to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sur, Daniel, Lungulescu, Cristina, Spînu, Ștefan, Gorzo, Alecsandra, Dumitrescu, Elena-Adriana, Gheonea, Dan Ionut, Lungulescu, Cristian-Virgil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606616/
https://www.ncbi.nlm.nih.gov/pubmed/36313317
http://dx.doi.org/10.3389/fphar.2022.1041927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606616/
https://www.ncbi.nlm.nih.gov/pubmed/36313317
http://dx.doi.org/10.3389/fphar.2022.1041927

Ejemplares similares